Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: the ELPIS phase I trial

Abstract Aims Hypoplastic left heart syndrome (HLHS) survival relies on surgical reconstruction of the right ventricle (RV) to provide systemic circulation. This substantially increases the RV load, wall stress, maladaptive remodelling, and dysfunction, which in turn increases the risk of death or transplantation. Methods and results We conducted a phase 1 open-label multicentre trial to assess the safety and feasibility of Lomecel-B as an adjunct to second-stage HLHS surgical palliation. Lomecel-B, an investigational cell therapy consisting of allogeneic medicinal signalling cells (MSCs), was delivered via intramyocardial injections. The primary endpoint was safety, and measures of RV function for potential efficacy were obtained. Ten patients were treated. None experienced major adverse cardiac events. All were alive and transplant-free at 1-year post-treatment, and experienced growth comparable to healthy historical data. Cardiac magnetic resonance imaging (CMR) suggested improved tricuspid regurgitant fraction (TR RF) via qualitative rater assessment, and via significant quantitative improvements from baseline at 6 and 12 months post-treatment (P < 0.05). Global longitudinal strain (GLS) and RV ejection fraction (EF) showed no declines. To understand potential mechanisms of action, circulating exosomes from intramyocardially transplanted MSCs were examined. Computational modelling identified 54 MSC-specific exosome ribonucleic acids (RNAs) corresponding to changes in TR RF, including miR-215-3p, miR-374b-3p, and RNAs related to cell metabolism and MAPK signalling. Conclusion Intramyocardially delivered Lomecel-B appears safe in HLHS patients and may favourably affect RV performance. Circulating exosomes of transplanted MSC-specific provide novel insight into bioactivity. Conduct of a controlled phase trial is warranted and is underway. Trial registration number NCT03525418.

[1]  R. Bolli,et al.  Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury , 2022, iScience.

[2]  D. Tucker,et al.  The Improved Prognosis of Hypoplastic Left Heart: A Population-Based Register Study of 343 Cases in England and Wales , 2021, Frontiers in Pediatrics.

[3]  Timothy J. Nelson,et al.  Clinical Impact of Autologous Cell Therapy on Hypoplastic Left Heart Syndrome after Bidirectional Cavopulmonary Anastomosis. , 2020, Seminars in thoracic and cardiovascular surgery.

[4]  M. Galantowicz,et al.  Tricuspid Valve and Right Ventricular Function Throughout the Hybrid Palliation Strategy for Hypoplastic Left Heart Syndrome and Variants , 2020, World journal for pediatric & congenital heart surgery.

[5]  T. Nelson,et al.  Loss of Ventricular Function After Bidirectional Cavopulmonary Connection: Who Is at Risk? , 2020, Pediatric Cardiology.

[6]  G. Di Salvo,et al.  Serial changes in longitudinal strain are associated with outcome in children with hypoplastic left heart syndrome. , 2020, International journal of cardiology.

[7]  Timothy J. Nelson,et al.  Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of intraoperative intramyocardial injections. , 2019, The Journal of thoracic and cardiovascular surgery.

[8]  M. Pittenger,et al.  Mesenchymal stem cell perspective: cell biology to clinical progress , 2019, npj Regenerative Medicine.

[9]  Peixin Yang,et al.  Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium , 2019, Science Translational Medicine.

[10]  M. Janowski,et al.  Concise Review: Mesenchymal Stem Cells: From Roots to Boost , 2019, Stem cells.

[11]  R. Bolli,et al.  Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions , 2018, Circulation research.

[12]  S. Sano,et al.  Impact of Cardiac Progenitor Cells on Heart Failure and Survival in Single Ventricle Congenital Heart Disease , 2018, Circulation research.

[13]  W. Ravekes,et al.  Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. , 2017, American heart journal.

[14]  J. Hare,et al.  Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials , 2017, Circulation research.

[15]  Shuhei Sato,et al.  Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology The PERSEUS ( Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease ) Randomized Phase 2 Trial , 2017 .

[16]  R. Hendel,et al.  Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. , 2017, Journal of the American College of Cardiology.

[17]  C. Mastropietro,et al.  Hypoplastic left heart syndrome: from comfort care to long-term survival , 2016, Pediatric Research.

[18]  P. Nguyen,et al.  Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review. , 2016, JAMA cardiology.

[19]  T. Schaeffter,et al.  Right ventricular morphology and function following stage I palliation with a modified Blalock–Taussig shunt versus a right ventricle-to-pulmonary artery conduit , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  B. Griffith,et al.  Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload. , 2016, American journal of physiology. Heart and circulatory physiology.

[21]  S. Sano,et al.  Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. , 2015, The Journal of thoracic and cardiovascular surgery.

[22]  B. Hurwitz,et al.  Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells , 2015, EBioMedicine.

[23]  Shuhei Sato,et al.  Intracoronary Autologous Cardiac Progenitor Cell Transfer in Patients With Hypoplastic Left Heart Syndrome: The TICAP Prospective Phase 1 Controlled Trial , 2015, Circulation research.

[24]  R. Bonow,et al.  Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). , 2014, Journal of the American College of Cardiology.

[25]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[26]  N. Hills,et al.  Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease. , 2012, The American journal of cardiology.

[27]  Gerard R Martin,et al.  Hypoplastic left heart syndrome: current considerations and expectations. , 2012, Journal of the American College of Cardiology.

[28]  Peter A. Altman,et al.  Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy: Functional Recovery and Reverse Remodeling , 2011, Circulation research.

[29]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[30]  H. S. Bernstein,et al.  Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. , 2009, The American journal of cardiology.

[31]  Matthew J Strickland,et al.  Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. , 2008, The Journal of pediatrics.

[32]  R. Chang,et al.  Decreasing number of deaths of infants with hypoplastic left heart syndrome. , 2008, The Journal of pediatrics.

[33]  S. Perez,et al.  Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells , 2006, Stem cells.

[34]  D. Barron,et al.  Staged surgical management of hypoplastic left heart syndrome: a single institution 12 year experience , 2005, Heart.

[35]  Yi Zhang,et al.  Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. , 2005, Blood.

[36]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[37]  J. Hoffman,et al.  The incidence of congenital heart disease. , 2002, Journal of the American College of Cardiology.

[38]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[39]  D. Fruitman,et al.  Hypoplastic left heart syndrome: Prognosis and management options. , 2000, Paediatrics & child health.

[40]  T. Massaro,et al.  Management of hypoplastic left heart syndrome in a consortium of university hospitals. , 1995, The American journal of cardiology.

[41]  Kevin McIntosh,et al.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. , 2002, Experimental hematology.